Acura Pharmaceuticals
ACUR
ACUR was delisted on the 22nd of February, 2017.
22 hedge funds and large institutions have $7.14M invested in Acura Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 22 → 22 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
36% less capital invested
Capital invested by funds: $11.1M → $7.14M (-$3.99M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$52.8K |
| 2 |
Renaissance Technologies
New York
|
+$45.2K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.35K |
| 4 |
SEI Investments
Oaks,
Pennsylvania
|
+$335 |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$330 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$337K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$3.61K |
| 3 |
Walleye Trading
New York
|
-$2.85K |
| 4 |
Morgan Stanley
New York
|
-$1.21K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$1K |
ACUR Hedge Fund Activity: Q2 2016 in Review
22 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Acura Pharmaceuticals (ACUR) for Q2 2016, worth a combined $7.14M — down 36% from $11.1M a quarter earlier.
Fund positioning in ACUR was balanced in Q2 2016: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $52.8K. The largest seller was Sabby Management, cutting an estimated $337K.
- 22 institutional investors held Acura Pharmaceuticals (ACUR) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $7.14M of Acura Pharmaceuticals stock for Q2 2016, down 36% quarter-over-quarter.
- 2 funds opened new Acura Pharmaceuticals positions in Q2 2016 and 2 closed out, a net change of 0 holders.
- The largest Acura Pharmaceuticals buyer in Q2 2016 was Virtu KCG Holdings, an estimated $52.8K added.
- The largest Acura Pharmaceuticals seller in Q2 2016 was Sabby Management, an estimated $337K sold.
Based on aggregated 13F filings for Q2 2016.